MeSH tree: N06.850.520.450.250.250.200
The early-stage trial of a potential novel nonartemisinin malaria drug found it rapidly killed malaria parasites and was generally well tolerated in infected volunteers, showing it is a promising candidate for uncomplicated ...
Jul 15, 2026
0
6
Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis. Patient outcomes have remained largely unchanged ...
Jul 10, 2026
0
13
Known by acronyms that need no explanation, viruses like COVID, SARS and Ebola conjure images of medics in protective suits and spark fear in populations worldwide.
Jun 25, 2026
0
11
Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell's "powerhouse." Unlike healthy cells, cancer ...
Jun 2, 2026
0
8
A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key ...
May 2, 2026
0
23
Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to a reduction in lesion size and allowed some patients to avoid surgery, according to research from a Phase I clinical trial presented at the American ...
Apr 21, 2026
0
13
Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 ...
Apr 20, 2026
0
3
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D ...
Apr 20, 2026
0
6
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according ...
Apr 20, 2026
0
6
Findings from two early clinical studies suggest a new dual-action antimalarial drug candidate is well tolerated in humans. The first-in-class clinical candidate, MK7602, is being developed by WEHI and global biopharmaceutical ...
Mar 19, 2026
0
20
